Treatment effect estimates in multi-arm multi-stage (MAMS) clinical trials

Published on June 30, 2020   39 min

Other Talks in the Category: Methods

0:00
This talk is about the analysis and the issue of bias in the estimate of treatment effects in multi-arm multi-stage randomised clinical trials designs. I'm Babak Oskooei, I'm a statistician at the MRC Clinical Trials Unit at UCL in London.
0:19
The outline of my talk is, first, I'm going to give you some introduction to clinical trials in general, and then I'm going to move on to just give a brief overview of multi-arm multi-stage randomised trials which is one type of adaptive designs. I'm going to go through the basic principles and give you some details, and then I'll move on to the issue of estimation of treatment effect. I'm going to go through that relevant issues at the definition of bias in a two-arm multi-stage setting, that is TAMS setting. Then for this presentation, I use real trial data to show how the stopping rules that we have in the multi-arm multi-stage setting which is a generalised version of group sequential designs, might affect their estimates of treatment effect in those trials. I'm going to re-design and re-analyse those four trials, mainly cancer trials. Then I'm going to explore the proposed methods to reduce the potential bias we might have because of these stopping rules in our design, and then finally, conclusions.
1:30
Usually, treatments or treatment regimens go through different phases in the course of their development. In this talk, I'm focusing on mainly Phase II/Phase III setting, where several such treatments or treatment combinations or those regimens might be available for testing in those late-phase trials. We know that in those settings, especially in cancer trials, those trials can be quite large and lengthy trials. The aim is to minimise patient exposure to toxic or ineffective treatments, and also reduce the cost. They can cost sometimes millions of dollars or pounds, and they can take up to 5-15 years depending on the disease area to do. Another aim would be to reduce costs incurred to ineffective treatments. For that reason, we need a design that allows faster and more effective evaluation of several treatments against the gold standard of control group as we have in this setting at the same time.
Hide

Treatment effect estimates in multi-arm multi-stage (MAMS) clinical trials

Embed in course/own notes